Sanofi has revealed its intention to purchase Blueprint Medicines, a US-based firm, boosting its immunology division with a $9.1 billion cash transaction, along with an extra $400 million depending on achieving performance milestones. This tactical acquisition encompasses Blueprint’s approved medication Avaykyt (avapritinib), which is prescribed for gastrointestinal stromal tumors and systemic mastocytosis, with projected sales of $479 million for 2024 and expected growth. Moreover, the agreement provides Sanofi with access to Blueprint’s promising drug development pipeline, featuring a candidate in phase 2/3 trials alongside other early-stage initiatives, positioning Sanofi for growth and innovation in immunology treatments.